Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 45 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/30/2007 First Published: 6/1/2000


1.		Phase I/II Study of Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Followed by Nonmyeloablative Allogeneic PBSC Transplantation in Patients With Refractory or Relapsed Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				65 and under				NCI				FHCRC-1409.00 NCI-G00-1776, NCT00005803

Last Modified: 8/23/2008 First Published: 12/1/2001


2.		Phase I/II Study of Immunotherapy With Armed Activated T Cells, Interleukin-2, and Sargramostim (GM-CSF) in Women With Stage IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI, Other				WSU-2006-130 NCT00027807, RWMC-0635146, WSU-010307M1F, WSU-0312004412

Last Modified: 3/28/2008 First Published: 12/21/2002


3.		Phase I/II Study of Vaccinia-CEA-TRICOM Vaccine Before Dose-Intensive Induction Chemotherapy and Fowlpox-CEA-TRICOM Vaccine After Dose-Intensive Induction Chemotherapy and Immune Depletion in Patients With Previously Untreated Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				NCI-03-C-0040 NCI-5762, 03-C-0040, NCT00053170


4.		GVAX in Advanced Prostate Cancer Patients Made Lymphopenic

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				PPMC-EACRI-IRB-02-119 DOD Grant #DAMD17-03-1-0097, NCT00122005

Last Modified: 9/19/2007 First Published: 4/7/2006


5.		Phase I/II Randomized Study of Vaccination Comprising MART-1/gp100/Tyrosinase/NY-ESO-1/MAGE-3 Peptide-Pulsed Dendritic Cells Matured Using Cytokines in Combination With Autologous Lymphocyte Infusion With or Without Fludarabine in Patients With Chemotherapy-Naïve Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				16 and over				NCI				MCC-13649 LAC-USC-10M-05-2, 6241, NCI-6241, LAC-USC-HS-05-00068, NCT00313508


6.		Autologous Cytokine-Induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				12 to 75				Other				CIK#1/2006 NCT00394381

Last Modified: 10/1/2008 First Published: 7/6/2007


7.		Phase I/II Study of Autologous Stem Cell Transplantation after Chemotherapy and Immunotherapy Followed by Thalidomide in Patients With High-Risk or Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 to 80				NCI				MSGCC-0610-GCC 0610 GCC, UPCC-0610-GCC, NCT00499577

Last Modified: 9/25/2008 First Published: 11/29/2007


8.		Phase I/II Study of Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation for Newly Diagnosed Stage II or III Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				JHOC-J0770 J0770, NCT00566098

Last Modified: 6/12/2008 First Published: 2/27/2008


9.		Phase I/II Randomized Study of Cytomegalovirus-Specific T-Cell Adoptive Transfer in Patients With Newly Diagnosed Glioblastoma Multiforme Who Are Recovering From Therapeutic Temozolomide-Induced Lymphopenia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Diagnostic, Treatment				Active				18 and over				NCI				DUMC-PRO00000580 PRO00000580, DUMC-SPORE Project 3, NCT00627224

Last Modified: 8/26/2008 First Published: 2/27/2008


10.		Phase I/II Randomized Study of Standard Chemoradiotherapy Followed by PEP-3-KLH Conjugate Vaccine With Versus Without Daclizumab in Patients With Resected Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				DUMC-PRO00000947 PRO00000947, DUMC-SPORE II 2003 CMV Grant, NCT00626015

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute